

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Immunotech Biopharm Ltd

永泰生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6978)

VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN THE PHASE I CLINICAL TRIAL FOR 6B11-OCIK INJECTION

Reference is made to the announcements of Immunotech Biopharm Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”), a leading cellular immunotherapy biopharmaceutical company in China focusing on the research, development, and commercialisation of T cell immunotherapy, dated 11 March 2021 and 4 August 2021 (the “**Announcements**”), on the development progress of Injection of Ovarian Cancer Autologous Cytotoxic T Lymphocyte (“**6B11-OCIK Injection**”), one of the Group’s pipeline products. Capitalised terms in this announcement shall have the same meanings as defined in the Announcements, unless otherwise defined.

6B11-OCIK INJECTION – FIRST PATIENT ENROLLMENT

The Company announces that 6B11-OCIK Injection, one of the Group’s pipeline products, has completed the first patient enrollment for its Phase I clinical trial in the PRC on 29 January 2022, which marked the milestone of the Group’s development in its product pipeline. Based on the progress of clinical trial for 6B11-OCIK Injection and barring unforeseen circumstances, it is expected that the targeted patient enrollment will complete in as early as the third quarter of 2022 and the preliminary analysis and results will be published in 2022.

ABOUT THE 6B11-OCIK INJECTION

6B11-OCIK Injection is the monoclonal anti-idiotypic antibody prepared by Beijing Weixiao Biotechnology Development Limited* (北京緯曉生物技術開發有限責任公司), a subsidiary of the Company, with COC166-9 immunised mice with monoclonal antibody to mimic ovarian cancer-related antigen OC166-9. The use of 6B11 can induce specific anti-ovarian cancer humoral and cellular immune antibodies in vitro, which can be cultured and proliferated in vitro (6B11-OCIK Injection) and infused back to the subject to achieve the purpose of specifically killing tumour cells.

ABOUT THE GROUP

The Group is a leading cellular immunotherapy biopharmaceutical company in China focusing on the research, development, and commercialisation of T cell immunotherapy for over 14 years. Since its establishment in 2006, it has focused on R&D and clinical applications of cellular immunotherapy drugs for cancers and other major diseases, by applying advanced theories in immunology, cell biology, and genetics.

Its product pipeline features major classes of cellular immunotherapy products, including both non-genetically-modified and genetically-modified products, as well as both multi-target and single-target products. Other than EAL[®], its main product candidates include the CAR-T cell series and the TCR-T cell series. To learn more about Immunotech, please visit www.eaal.net.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited: The Group cannot guarantee that 6B11-OCIK Injection will ultimately be successfully developed and marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Immunotech Biopharm Ltd
Tan Zheng
Chairman and executive Director

Hong Kong, 30 January 2022

As at the date of this announcement, the Board of the Company comprises Mr Tan Zheng as Chairman and executive Director, Dr Wang Yu and Mr Jung Hyun Chul as executive Directors, Mr Tao Ran, Mr Si Xiaobing and Mr Lu Yuan as non-executive Directors, and Professor Wang Yingdian, Mr Ng Chi Kit and Ms Peng Sujiu as independent non-executive Directors.

* *For identification purposes only*